BACKGROUND: "Conditional survival probability" is defined as the probability that a patient will survive an additional time, given that the patient has already survived a defined period of time after diagnosis. Such estimates might be more relevant for clinicians and patients during post-diagnosis care, because survival probability projections are based on the patient's survival to date. Here, we provides the first population-based estimates of conditional survival probabilities by histology for brain cancer in Canada. METHODS: Canadian Cancer Registry data were accessed for patients diagnosed with primary brain cancers during 2000-2008. Kaplan-Meier survival probabilities were estimated by histology. Conditional survival probabilities at 6 months (short-term, denoted scs) and 2 years (long-term, denoted lcs) were derived from the Kaplan-Meier survival estimates for a range of time periods. RESULTS: Among the 20,875 patients who met the study criteria, scs increased by a margin of 16-18 percentage points from 6-month survivors to 2-year survivors for the three most aggressive brain cancers. The lcs for 2-year survivors was 66% or greater for all tumour groups except glioblastoma. The lcs for 4-year survivors was 62% or greater for all histologies. For glioblastoma and diffuse astrocytoma, the lcs increased each year after diagnosis. For all other histologies, the lcs first increased and then plateaued from 2 years after diagnosis. The lcs and scs both worsened with increasing older age at diagnosis. SUMMARY: We report histologically specific conditional survival probabilities that can have value for clinicians practicing in Canada as they plan the course of follow-up for individual patients with brain cancer.
BACKGROUND: "Conditional survival probability" is defined as the probability that a patient will survive an additional time, given that the patient has already survived a defined period of time after diagnosis. Such estimates might be more relevant for clinicians and patients during post-diagnosis care, because survival probability projections are based on the patient's survival to date. Here, we provides the first population-based estimates of conditional survival probabilities by histology for brain cancer in Canada. METHODS: Canadian Cancer Registry data were accessed for patients diagnosed with primary brain cancers during 2000-2008. Kaplan-Meier survival probabilities were estimated by histology. Conditional survival probabilities at 6 months (short-term, denoted scs) and 2 years (long-term, denoted lcs) were derived from the Kaplan-Meier survival estimates for a range of time periods. RESULTS: Among the 20,875 patients who met the study criteria, scs increased by a margin of 16-18 percentage points from 6-month survivors to 2-year survivors for the three most aggressive brain cancers. The lcs for 2-year survivors was 66% or greater for all tumour groups except glioblastoma. The lcs for 4-year survivors was 62% or greater for all histologies. For glioblastoma and diffuse astrocytoma, the lcs increased each year after diagnosis. For all other histologies, the lcs first increased and then plateaued from 2 years after diagnosis. The lcs and scs both worsened with increasing older age at diagnosis. SUMMARY: We report histologically specific conditional survival probabilities that can have value for clinicians practicing in Canada as they plan the course of follow-up for individual patients with brain cancer.
Authors: Quinn T Ostrom; Luc Bauchet; Faith G Davis; Isabelle Deltour; James L Fisher; Chelsea Eastman Langer; Melike Pekmezci; Judith A Schwartzbaum; Michelle C Turner; Kyle M Walsh; Margaret R Wrensch; Jill S Barnholtz-Sloan Journal: Neuro Oncol Date: 2014-07 Impact factor: 12.300
Authors: Mei-Yin C Polley; Kathleen R Lamborn; Susan M Chang; Nicholas Butowski; Jennifer L Clarke; Michael Prados Journal: J Clin Oncol Date: 2011-10-03 Impact factor: 44.544
Authors: Faith G Davis; Beatrice S Malmer; Ken Aldape; Jill S Barnholtz-Sloan; Melissa L Bondy; Thomas Brännström; Janet M Bruner; Peter C Burger; V Peter Collins; Peter D Inskip; Carol Kruchko; Bridget J McCarthy; Roger E McLendon; Siegal Sadetzki; Tarik Tihan; Margaret R Wrensch; Patricia A Buffler Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-03 Impact factor: 4.254
Authors: C L Lin; A S Lieu; K S Lee; Y H C Yang; T H Kuo; M H Hung; J K Loh; C P Yen; C Z Chang; S L Howng; S L Hwang Journal: Surg Neurol Date: 2003-11
Authors: Paul Farah; Rachel Blanda; Courtney Kromer; Quinn T Ostrom; Carol Kruchko; Jill S Barnholtz-Sloan Journal: J Neurooncol Date: 2016-04-19 Impact factor: 4.130
Authors: David N Louis; Arie Perry; Peter Burger; David W Ellison; Guido Reifenberger; Andreas von Deimling; Kenneth Aldape; Daniel Brat; V Peter Collins; Charles Eberhart; Dominique Figarella-Branger; Gregory N Fuller; Felice Giangaspero; Caterina Giannini; Cynthia Hawkins; Paul Kleihues; Andrey Korshunov; Johan M Kros; M Beatriz Lopes; Ho-Keung Ng; Hiroko Ohgaki; Werner Paulus; Torsten Pietsch; Marc Rosenblum; Elisabeth Rushing; Figen Soylemezoglu; Otmar Wiestler; Pieter Wesseling Journal: Brain Pathol Date: 2014-09-10 Impact factor: 6.508
Authors: Anouk E J Latenstein; Stijn van Roessel; Lydia G M van der Geest; Bert A Bonsing; Cornelis H C Dejong; Bas Groot Koerkamp; Ignace H J T de Hingh; Marjolein Y V Homs; Joost M Klaase; Valery Lemmens; I Quintus Molenaar; Ewout W Steyerberg; Martijn W J Stommel; Olivier R Busch; Casper H J van Eijck; Hanneke W M van Laarhoven; Johanna W Wilmink; Marc G Besselink Journal: Ann Surg Oncol Date: 2020-02-12 Impact factor: 5.344
Authors: Joshua D Palmer; Gordon Chavez; Wesley Furnback; Po-Ya Chuang; Bruce Wang; Christina Proescholdt; Chao-Hsiun Tang Journal: Front Oncol Date: 2021-12-02 Impact factor: 6.244